# Empagliflozin and Sympathetic Nerve Traffic

> **NCT03254849** · PHASE4 · COMPLETED · sponsor: **Profil Institut für Stoffwechselforschung GmbH** · enrollment: 75 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Hydrochlorothiazide 25 mg

## Key facts

- **NCT ID:** NCT03254849
- **Lead sponsor:** Profil Institut für Stoffwechselforschung GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-08
- **Primary completion:** 2020-04-20
- **Final completion:** 2020-04-20
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2020-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03254849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03254849, "Empagliflozin and Sympathetic Nerve Traffic". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03254849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*